The conference presented by Alzheimer’s Drug Discovery Foundation & Institute for the Study of Aging and will provide academic and biotechnology scientists with an overview of the drug discovery, development and delivery process, emphasizing the steps needed to translate basic research into CNS-targeted therapies. Alzheimer disease, Parkinson disease, Huntington disease, and ALS will be included in the discussions.

The Institute for the Study of Aging (ISOA) is a biomedical venture philanthropy whose sole mission is to accelerate the discovery and development of new drugs to prevent, treat and cure Alzheimer's disease and related dementias. Since its founding as a private foundation by the Lauder family in 1998, ISOA has awarded $24M for 143 research programs and conferences worldwide.

In 2004, the Lauder family established a public charity, the Alzheimer’s Drug Discovery Foundation, to enable individuals, foundations and corporations to partner with the Institute in an effort to raise additional funds and award more grants.

Monika Halarewicz
Email: MHalarewicz@alzdiscovery.org